Our robust pipeline comprises high value proprietary assets.

To create and capture the value of our pipeline we have built a strong, vibrant network between academia and various strategic partners, enabling us to leverage their strengths and capabilities, alongside our own, to progress our pipeline safely and expediently through the clinic.


NVG-111 is a first-in-class bispecific T cell engager (TCE) antibody targeting Receptor Tyrosine Kinase Like Orphan Like Receptor 1 (ROR1) expressing tumors and designed to be highly effective in the killing of cancer cells, without the depletion of normal B cells. The NVG-111 program will initially focus on hematological malignancies to establish proof of concept prior to moving to hard-to-treat solid tumors.

NovalGen’s proprietary ROR1 and CD3 humanized binding arms have been engineered to provide optimal T cell engagement and efficient killing of tumor target cells without excessive release of cytokines. In addition, NVG-111 can target cancer initiating stem cells (CSCs), a subpopulation of cancer cells that are resistant to standard cancer therapies. It is the only T cell engager in development that can kill CSCs, potentially reducing the risk of tumor recurrence.

Gohil et al https://doi.org/10.1080/2162402X.2017.1326437 and https://doi.org/10.1111/bjh.15911


NVG-222 is an extended-half-life version of NovalGen’s clinically derisked NVG-111 bispecific T cell engager. Designed with the same ROR1 and CD3 binding arms, NVG-222 comprises our novel, proprietary auto-regulation technology. This breakthrough technology has been smart-designed to inactivate NVG-222 in settings where there is risk of life threatening toxicity without impacting on efficacy.

This technology offers the potential for a paradigm shift in immune-oncology therapies, delivering safer treatments for cancer patients without sacrificing therapeutic efficacy.


NVG-333 is our next generation of ROR1 targeting armored CAR-T cell with inducible secretion of a dual payload in response to tumor cell engagement (biCAR). In addition to the direct killing of cancer cells, the dual payload will be delivered specifically into the tumour microenvironment (TME) to enhance NVG-333 cytotoxic efficacy as well as activating resident tumor infiltrating T cells. Built into these biCARs is our ground-breaking auto-regulation technology adapted to CAR T cells that will maintain long-term tolerability and safety profile.

This approach addresses the efficacy and safety concerns of CAR-T cells and can be leveraged across a range of cellular therapies.


NVG-444 is a next generation of bispecific antibodies aimed at different targets that includes our proprietary auto-regulation technology.

Futher reading

Our technologies

We are changing the paradigm of cancer therapy with our immunotherapy technology

Read more

Patients and families

We work with families and patient organisations to ensure our programmes deliver the best treatments for patients.

Read more